Abstract
Current guidelines for patients who are undergoing transcatheter aortic valve implantation but who do not require anticoagulation recommend double antiplatelet therapy for 3-6 months after the procedure, followed by aspirin indefinitely. However, these guidelines are based on expert consensus rather than clinical trials. Several randomized trials are currently evaluating alternative antithrombotic strategies, and recommendations will likely change when their results become available.
MeSH terms
-
Anticoagulants / therapeutic use
-
Aspirin / therapeutic use
-
Fibrinolytic Agents / therapeutic use*
-
Heart Valve Diseases / diagnosis
-
Heart Valve Diseases / drug therapy*
-
Heart Valve Diseases / surgery*
-
Humans
-
Postoperative Complications / diagnosis
-
Postoperative Complications / prevention & control
-
Risk Factors
-
Transcatheter Aortic Valve Replacement / adverse effects
-
Transcatheter Aortic Valve Replacement / trends*
Substances
-
Anticoagulants
-
Fibrinolytic Agents
-
Aspirin